Analyzing Tilray Brands (NASDAQ:TLRY) & Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Insider and Institutional Ownership

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 10.5% of Capricor Therapeutics shares are held by insiders. Comparatively, 0.8% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Capricor Therapeutics and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-62.71%	-50.82%
Tilray Brands	-258.54%	-6.79%	-5.30%

Analyst Recommendations

This is a summary of current ratings and target prices for Capricor Therapeutics and Tilray Brands, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1	0	7	1	2.89
Tilray Brands	2	3	2	0	2.00

Capricor Therapeutics currently has a consensus target price of $22.25, suggesting a potential upside of 275.21%. Tilray Brands has a consensus target price of $2.00, suggesting a potential upside of 61.29%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Capricor Therapeutics is more favorable than Tilray Brands.

Earnings and Valuation

This table compares Capricor Therapeutics and Tilray Brands”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$13.39 million	20.24	-$40.47 million	($1.64)	-3.62
Tilray Brands	$821.31 million	1.70	-$2.19 billion	($2.27)	-0.55

Capricor Therapeutics has higher earnings, but lower revenue than Tilray Brands. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Capricor Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Summary

Capricor Therapeutics beats Tilray Brands on 10 of the 15 factors compared between the two stocks.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.